Travere Therapeutics (TVTX) Non-Current Deffered Revenue (2021 - 2024)

Travere Therapeutics has reported Non-Current Deffered Revenue for 4 years, with the latest figure at $888000.0 in Q1 2024.

• For the quarter ending Q1 2024, Non-Current Deffered Revenue fell 89.88% year-over-year to $888000.0; the trailing twelve-month figure through Mar 2024 stood at $888000.0 (down 89.88% YoY), and the FY2023 full-year result was $1.8 million, down 83.21% from the prior year.
• Non-Current Deffered Revenue for Q1 2024 stood at $888000.0, down from $1.8 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $24.1 million in Q3 2021, with the low at $888000.0 in Q1 2024.
• Historically, Non-Current Deffered Revenue has averaged $11.6 million across 4 years, with a median of $10.9 million in 2022.
• Annual changes were most pronounced in 2022 — Non-Current Deffered Revenue slumped 46.36% — and 2024, when it tumbled 89.88%.
• Travere Therapeutics' Non-Current Deffered Revenue stood at $20.4 million in 2021, then slumped by 46.36% to $10.9 million in 2022, then slumped by 83.21% to $1.8 million in 2023, then plunged by 51.61% to $888000.0 in 2024.
• The last three Non-Current Deffered Revenue figures came in at $888000.0 (Q1 2024), $1.8 million (Q4 2023), and $4.6 million (Q3 2023), per Business Quant data.